Brief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
12/10/2026 02:11
BRIEF-Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators Oct 12 (Reuters) - Transcenta Holding Ltd 6628.HK:
GLOBAL PHASE III TRIAL OF OSEMITAMAB (TST001) APPROVED BY FDA, CHINA, KOREA REGULATORS
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.